Tags » GlaxoSmithKline

GSK attracts negative rating news coverage as analysts turn bearish on stock

Analysts’ bearish stance on GSK weighs on stock price heavily

Media coverage for GlaxoSmithKline Plc, one of the world’s largest drug makers was dominated by Stock Rating related news items in the past 90-days.  244 more words

Home

PHOTOS: The Incredible Advances We've Made in the War Against HIV on World AIDS Day

Friday marks World AIDS Day, an occasion for recognizing the myriad struggles, successes, and work left undone—societal, political, and medical alike—in the battle against HIV infection and the immune system-compromising disease it causes, AIDS. 437 more words

Health

Critical Collaboration Agreements for Ebola Vaccine Candidates Earn NIAID an Excellence in Technology Transfer Award

In 2014, as the Ebola outbreak escalated, NIAID collaborated with pharmaceutical company GlaxoSmithKline (GSK) on NIAID-planned clinical trials to test Ebola vaccine candidates. Their collaboration exemplifies the flexibility and creativity of the NIAID Technology Transfer and Intellectual Property Office (TTIPO), who developed unique and expedited agreements to facilitate the development of an Ebola vaccine. 424 more words

Diseases

Elesclomol

Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. 33 more words

API

Pharmaceuticals can be a license to print money

By Pete Dolack | Systemic Disorder | October 11, 2107

It’s no secret that the United States suffers from by far the world’s highest costs for health care.

1,086 more words
United States

Global Autoimmune Treatment Market Report and Forecast to 2021

In this report, the global Autoimmune Treatment market is valued at USD XX million in 2017 and is projected to reach USD XX million by the end of 2021, growing at a… 489 more words

Heavy Industries

GlaxoSmithKline posts positive results from Trelegy Ellipta study

GlaxoSmithKline’s positivity around its Trelegy Ellipta product continued on Wednesday, as the company – alongside US firm Innoviva – announced headline results from the landmark phase III IMPACT study.

8 more words
Scoop.it